Nama's AI scorecard currently rates Harrow Sell (1.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does HROW report earnings?

Harrow's next scheduled report is on Nov 9, 2026. Analysts expect EPS of $0.32.

What is the HROW price target?

The median analyst price target from 8 analysts is $60.00, with a range of $45.00 – $88.00.

Is HROW Shariah compliant?

Nama's AAOIFI-style screen reads Harrow as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Harrow (HROW)

Healthcare · Drug Manufacturers Specialty Generic · NASDAQ

Harrow (HROW) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $1.01B and a free-cash-flow yield of 4.3%. Over the most recent reported fiscal year, revenue grew 36.4%. Nama's AI scorecard rates it Sell, 1.9 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 1.9/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Lagging · -11.1% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-54.6%

How far the last close sits under the highest price of the past five years.

Market cap	$1.01B
Trailing P/E	—
Price / book	65.6
Price / sales	3.7
FCF yield	4.3%
Dividend yield	—
Gross margin	73.3%
Operating margin	-1.0%
Net margin	-13.5%
Revenue growth (YoY)	+36.4%
Revenue growth (3-yr annual)	+45.4%
EPS growth (YoY)	+4500.0%
FCF/share growth (YoY)	—
Beta	0.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

HROW earnings

Next report: Nov 9, 2026 (Q3 2026, EPS estimate $0.32). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 10, 2026	-$0.46	-$0.24	-91.7%	$70.66M
Q1 2026	May 11, 2026	-$0.74	-$0.33	-124.2%	$44.20M
Q4 2025	Mar 2, 2026	$0.27	$0.48	-43.8%	$89.09M
Q3 2025	Nov 10, 2025	$0.33	$0.29	+13.8%	$71.64M

HROW analyst price target

Median target $60.00 from 8 analysts, ranging $45.00 – $88.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3

Explore live HROW data on Nama Insights →

HROW FAQ

Is HROW a buy?: Nama's AI scorecard currently rates Harrow Sell (1.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does HROW report earnings?: Harrow's next scheduled report is on Nov 9, 2026. Analysts expect EPS of $0.32.
What is the HROW price target?: The median analyst price target from 8 analysts is $60.00, with a range of $45.00 – $88.00.
Is HROW Shariah compliant?: Nama's AAOIFI-style screen reads Harrow as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.